Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Fig. 2

Prescribing glucagon-like peptide-1 receptor agonist (GLP-1RA) plus sodium-glucose cotransporter-2 inhibitor (SGLT2i) combination therapy in patients with type 2 diabetes mellitus. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; HbA1c, hemoglobin A1c; HFrEF, heart failure with reduced ejection fraction; MRF, multiple risk factors. *MRF include advanced age, hypertension, dyslipidemia, smoking, obesity, proteinuria, and left ventricular hypertrophy. **GLP-1RAs should be avoided in patients with HFrEF, as they did not demonstrate a beneficial effect on left ventricular function, with a trend towards harm

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840